Harmony Biosciences posts Q3 revenue growth but EPS miss, shares slide
+1 new source since this summary was written
Harmony Biosciences reported third‑quarter 2026 revenue of $268.9 million, a 12% year‑over‑year increase, and reaffirmed its full‑year net‑revenue guidance of $1.0 billion‑$1.04 billion. Net income fell to $48.2 million and diluted EPS slipped to $0.81, missing the consensus estimate of $1.11. The results triggered an 8.32% drop in the stock price to $33.94 as investors focused on higher royalty and milestone expenses.
Why it matters
The earnings miss and margin pressure led to an 8.32% share decline, indicating short‑term downside risk for investors. The reaffirmed revenue guidance suggests the company still expects to reach the $1 billion annual WAKIX target, which may support longer‑term upside.
Key facts
- 1Q3 2026 revenue was $268.9 million, up 12% YoY. tradingview.com
- 2Net income was $48.2 million, down from $50.9 million YoY. tradingview.com
- 3Diluted EPS was $0.81, missing the $1.11 consensus estimate. investing.com
- 4Full‑year 2026 net‑revenue guidance remains $1.0 billion‑$1.04 billion. tradingview.com
- 5Cash reserves were $1.05 billion as of Q3 2026. investing.com
- 6Shares fell 8.32% to $33.94 after the earnings release. investing.com
Summary written by AlphAI AI Desk from 4 of 4 sources. Not investment advice. Figures are as stated by the linked sources.